Plus Therapeutics Q1 2024 GAAP EPS $(0.75) Beats $(1.09) Estimate, Sales $1.677M Miss $1.688M Estimate
Plus Therapeutics Q1 2024 GAAP EPS $(0.75) Beats $(1.09) Estimate, Sales $1.677M Miss $1.688M Estimate
Plus Therapeutics 2024年第一季度GAAP每股收益美元（0.75美元）超過預期（1.09美元），銷售額爲16.77億美元，低於16.88萬美元的預期
Plus Therapeutics (NASDAQ:PSTV) reported quarterly losses of $(0.75) per share which beat the analyst consensus estimate of $(1.09) by 31.19 percent. This is a 63.77 percent increase over losses of $(2.07) per share from the same period last year. The company reported quarterly sales of $1.677 million which missed the analyst consensus estimate of $1.688 million by 0.62 percent. This is a 231.42 percent increase over sales of $506.000 thousand the same period last year.
Plus Therapeutics（納斯達克股票代碼：PSTV）公佈的季度虧損爲每股0.75美元（0.75美元），比分析師普遍預期的1.09美元（1.09美元）高出31.19％。這比去年同期每股虧損2.07美元（2.07）增長了63.77％。該公司公佈的季度銷售額爲16.77億美元，比分析師普遍預期的16.88萬美元低0.62％。這比去年同期的50.6萬美元銷售額增長了231.42％。